Literature DB >> 2481641

Murine membrane inhibitor of complement which accelerates decay of human C3 convertase.

Y Kameyoshi1, M Matsushita, H Okada.   

Abstract

A membrane protein of MW 60,000 was purified from mouse erythrocytes. This protein inhibits generation of mouse complement C3/C5 convertases on antibody-sensitized rabbit erythrocytes, in a haemolytic assay system using guinea-pig serum diluted in EDTA as the source of C3 to C9. This protein also has the capacity to accelerate the decay of human C3 convertase of the classical complement pathway. Antibody to this membrane protein also reacted with peripheral blood mononuclear cells and spleen cells, as observed by fluorescent flow cytometry analysis. Since the reactivity of these cells to the antibody was reduced by treatment with phosphatidyl inositol-specific phospholipase C (PIPLC), it is suggested that the protein is attached to the membrane via a glycophospholipid anchor. Based on these results, we conclude that this membrane protein is a murine homologue of human decay-accelerating factor (DAF).

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2481641      PMCID: PMC1385526     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  25 in total

1.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

2.  p65: A C3b-binding protein on murine cells that shares antigenic determinants with the human C3b receptor (CR1) and is distinct from murine C3b receptor.

Authors:  W W Wong; D T Fearon
Journal:  J Immunol       Date:  1985-06       Impact factor: 5.422

3.  Regulation of the amplification C3 convertase of human complement by an inhibitory protein isolated from human erythrocyte membrane.

Authors:  D T Fearon
Journal:  Proc Natl Acad Sci U S A       Date:  1979-11       Impact factor: 11.205

4.  The purification and reactivity of the first component of complement from guinea pig, human and canine sera.

Authors:  N Tamura; R A Nelson
Journal:  J Immunol       Date:  1968-12       Impact factor: 5.422

5.  Isolation of a human erythrocyte membrane glycoprotein with decay-accelerating activity for C3 convertases of the complement system.

Authors:  A Nicholson-Weller; J Burge; D T Fearon; P F Weller; K F Austen
Journal:  J Immunol       Date:  1982-07       Impact factor: 5.422

6.  Solubilization of membrane-bound acetylcholinesterase by a phosphatidylinositol-specific phospholipase C.

Authors:  A H Futerman; M G Low; D M Michaelson; I Silman
Journal:  J Neurochem       Date:  1985-11       Impact factor: 5.372

7.  Purification from guinea pig erythrocyte stroma of a decay-accelerating factor for the classical c3 convertase, C4b,2a.

Authors:  A Nicholson-Weller; J Burge; K F Austen
Journal:  J Immunol       Date:  1981-11       Impact factor: 5.422

8.  Regulatory proteins for the activated third and fourth components of complement (C3b and C4b) in mice. II. Identification and properties of complement receptor type 1 (CR1).

Authors:  T Kinoshita; S Lavoie; V Nussenzweig
Journal:  J Immunol       Date:  1985-04       Impact factor: 5.422

Review 9.  Distribution of decay-accelerating factor in the peripheral blood of normal individuals and patients with paroxysmal nocturnal hemoglobinuria.

Authors:  T Kinoshita; M E Medof; R Silber; V Nussenzweig
Journal:  J Exp Med       Date:  1985-07-01       Impact factor: 14.307

10.  Inhibition of complement activation on the surface of cells after incorporation of decay-accelerating factor (DAF) into their membranes.

Authors:  M E Medof; T Kinoshita; V Nussenzweig
Journal:  J Exp Med       Date:  1984-11-01       Impact factor: 14.307

View more
  17 in total

1.  The serum resistance of malaria-infected erythrocytes.

Authors:  Y Kawamoto; K Kojima; Y Hitsumoto; H Okada; V M Holers; A Miyama
Journal:  Immunology       Date:  1997-05       Impact factor: 7.397

2.  Role of decay-accelerating factor in regulating complement activation on the erythrocyte surface as revealed by gene targeting.

Authors:  X Sun; C D Funk; C Deng; A Sahu; J D Lambris; W C Song
Journal:  Proc Natl Acad Sci U S A       Date:  1999-01-19       Impact factor: 11.205

3.  Human complement regulatory proteins expressed on mouse A9 cells containing a human chromosome 1.

Authors:  T Seya; M Okada; T Hara; M Matsumoto; S Miyagawa; M Oshimura
Journal:  Immunology       Date:  1991-12       Impact factor: 7.397

4.  Tissue distribution of products of the mouse decay-accelerating factor (DAF) genes. Exploitation of a Daf1 knock-out mouse and site-specific monoclonal antibodies.

Authors:  F Lin; Y Fukuoka; A Spicer; R Ohta; N Okada; C L Harris; S N Emancipator; M E Medof
Journal:  Immunology       Date:  2001-10       Impact factor: 7.397

5.  Characterization of glycosylphosphatidylinositol-anchored decay accelerating factor (GPI-DAF) and transmembrane DAF gene expression in wild-type and GPI-DAF gene knockout mice using polyclonal and monoclonal antibodies with dual or single specificity.

Authors:  T Miwa; X Sun; R Ohta; N Okada; C L Harris; B P Morgan; W C Song
Journal:  Immunology       Date:  2001-10       Impact factor: 7.397

Review 6.  Membrane proteins that protect against complement lysis.

Authors:  B P Morgan; S Meri
Journal:  Springer Semin Immunopathol       Date:  1994

7.  Tissue distribution of the rat analogue of decay-accelerating factor.

Authors:  O B Spiller; S M Hanna; B P Morgan
Journal:  Immunology       Date:  1999-07       Impact factor: 7.397

8.  Tissue distribution of the guinea-pig decay-accelerating factor.

Authors:  K Nishikawa; S Matsuo; H Tamai; N Okada; H Okada
Journal:  Immunology       Date:  1998-10       Impact factor: 7.397

9.  Membrane protein Crry maintains homeostasis of the complement system.

Authors:  Xiaobo Wu; Dirk Spitzer; Dailing Mao; Stanford L Peng; Hector Molina; John P Atkinson
Journal:  J Immunol       Date:  2008-08-15       Impact factor: 5.422

10.  Mousepox in the C57BL/6 strain provides an improved model for evaluating anti-poxvirus therapies.

Authors:  Scott Parker; Akbar M Siddiqui; Christina Oberle; Ed Hembrador; Randall Lanier; George Painter; Alice Robertson; R Mark Buller
Journal:  Virology       Date:  2008-12-18       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.